Key Points
- CMO Harold Bernstein sold 25,156 shares on Jan. 7 at an average $40.20 for $1,011,271.20, and including three other recent sales (Dec. 29, Jan. 2, Jan. 5) has sold roughly $3.03 million of MAZE stock.
- MAZE shares opened at $40.32 (up ~3.5%), the company has a market cap of $1.94 billion and a 52‑week range of $6.71–$43.29, while analysts carry a consensus "Buy" rating with an average price target of $43.38.
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CMO Harold Bernstein sold 25,156 shares of the stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $40.20, for a total value of $1,011,271.20. The sale was disclosed in a document filed with the SEC, which is available through this link.
Harold Bernstein also recently made the following trade(s):
- On Monday, January 5th, Harold Bernstein sold 412 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.00, for a total value of $16,480.00.
- On Friday, January 2nd, Harold Bernstein sold 4,432 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.43, for a total value of $179,185.76.
- On Monday, December 29th, Harold Bernstein sold 45,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.56, for a total value of $1,825,200.00.
Maze Therapeutics Stock Up 3.5%
MAZE opened at $40.32 on Friday. The stock has a market capitalization of $1.94 billion and a price-to-earnings ratio of -1.93. Maze Therapeutics, Inc. has a twelve month low of $6.71 and a twelve month high of $43.29. The company has a 50-day simple moving average of $37.72 and a 200 day simple moving average of $25.85.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.08.
Institutional Investors Weigh In On Maze Therapeutics
A number of institutional investors have recently made changes to their positions in MAZE. CWM LLC bought a new stake in Maze Therapeutics in the second quarter valued at approximately $28,000. Ameritas Investment Partners Inc. increased its position in shares of Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock worth $42,000 after buying an additional 738 shares during the period. Russell Investments Group Ltd. raised its stake in Maze Therapeutics by 947.8% during the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company's stock worth $49,000 after buying an additional 1,725 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Maze Therapeutics during the third quarter valued at $52,000. Finally, Legal & General Group Plc grew its holdings in Maze Therapeutics by 387.0% during the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company's stock worth $52,000 after acquiring an additional 3,371 shares during the period.
Analyst Ratings Changes
A number of equities research analysts have weighed in on MAZE shares. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Maze Therapeutics in a report on Wednesday, October 8th. BTIG Research increased their price objective on shares of Maze Therapeutics from $30.00 to $37.00 and gave the company a "buy" rating in a research note on Friday, September 12th. Wedbush upped their price target on shares of Maze Therapeutics from $35.00 to $36.00 and gave the stock an "outperform" rating in a report on Friday, November 7th. JPMorgan Chase & Co. increased their price target on Maze Therapeutics from $27.00 to $37.00 and gave the company an "overweight" rating in a research note on Monday, September 29th. Finally, Guggenheim restated a "buy" rating and set a $46.00 price objective on shares of Maze Therapeutics in a research report on Friday, December 19th. Three analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $43.38.
Get Our Latest Research Report on Maze Therapeutics
Maze Therapeutics Company Profile
(
Get Free Report)
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
